Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions
Cancers · 28.08.2025 · 17 (17) · 2810
DOI: 10.3390/cancers17172810 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.08.2025. Verfasst von Said A Khelwatty und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Pharmacy and Chemistry, Kingston University London, London KT1 2EE, UK. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BRIGHT Charity UK, Better Research into Gastrointestinal Cancer Health and Treatment (BRIGHT), United Kingdom.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a significant global health burden. While early-stage CRC has a high survival rate, most patients are diagnosed with advanced disease, necessitating more effective and less toxic therapeutic targets. This review examines recent advancements, challenges, and future directions in targeted therapies for CRC, focusing on HER inhibitors. We assess the efficacy of monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) and explore strategies to overcome resistance mechanisms. Targeted therapies like cetuximab and panitumumab have improved outcomes for CRC patients with wild-type KRAS. However, resistance mechanisms and intra- and inter-tumour heterogeneity limit their effectiveness. Recent advancements include the development of dual TKIs, antibody/drug conjugates (ADCs), bispecific antibodies, and CAR-T cells against HER family members and other targets that are showing promise in preclinical and clinical trials. Targeted therapies have transformed CRC treatment, but more research is needed to overcome some of the current challenges, such as late diagnosis and the heterogenous nature of CRC, as well as the discovery of more reliable biomarkers for response to the therapy and patient selection. Future research should focus on identifying novel biomarkers of diagnostic, prognostic, and predictive value, developing next-generation inhibitors, drug repurposing, and combining small-molecule targeted therapies with immunotherapy. Such advances could ultimately help increase both the treatment options and outcomes for patients with CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Science, Pharmacy and Chemistry, Kingston University London, London KT1 2EE, UK.
- Faculty of health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK.
- Berkshire Surrey Pathology Services, Royal Surrey Hospital, Guildford GU2 7XX, UK.
- St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford GU2 7XX, UK.
ORCID-Profile: Said A Khelwatty, Helmout Modjtahedi
Förderung
- BRIGHT Charity UK
- Better Research into Gastrointestinal Cancer Health and Treatment (BRIGHT), United Kingdom
Zitieren
APA
Khelwatty, S. A., Puvanenthiran, S., Seddon, A. M., Bagwan, I., Essapen, S., & Modjtahedi, H. (2025). Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions. Cancers, 17(17), 2810. https://doi.org/10.3390/cancers17172810
Vancouver
Khelwatty SA, Puvanenthiran S, Seddon AM, Bagwan I, Essapen S, Modjtahedi H. Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions. Cancers. 2025;17(17):2810. doi:10.3390/cancers17172810
BibTeX
@article{Khelwatty2025,
author = {Khelwatty, Said A and Puvanenthiran, Soozana and Seddon, Alan M and Bagwan, Izhar and Essapen, Sharadah and Modjtahedi, Helmout},
title = {Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2810},
doi = {10.3390/cancers17172810}
}
EUVIMED